Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 8/2022

Open Access 01.02.2022 | Head and Neck

Changing trends in the microvascular reconstruction and oral rehabilitation following maxillary cancer

verfasst von: Simon N. Rogers, Ashni Adatia, Stephanie Hackett, Angela Boscarino, Anika Patel, Derek Lowe, Christopher J. Butterworth

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 8/2022

Abstract

Purpose

The maxillectomy defect is complex and the best means to achieve optimal reconstruction, and dental rehabilitation is a source of debate. The refinements in zygomatic implant techniques have altered the means and speed by which rehabilitation can be achieved and has also influenced the choice regarding ideal flap reconstruction. The aim of this study is to report on how the method of reconstruction and oral rehabilitation of the maxilla has changed since 1994 in our Institution, and to reflect on case mix and survival.

Methods

Consecutive head and neck oncology cases involving maxillary resections over a 27-year period between January 1994 and November 2020 were identified from hospital records and previous studies. Case note review focussed on clinical characteristics, reconstruction, prosthetic rehabilitation, and survival.

Results

There were 186 patients and the tumour sites were: alveolus for 56% (104), hard palate for 19% (35), maxillary sinus for 18% (34) and nasal for 7% (13). 52% (97) were Brown class 2 defects. Forty-five patients were managed by obturation and 78% (142/183) had free tissue transfer. The main flaps used were radial (52), anterolateral thigh (27), DCIA (22), scapula (13) and fibula (11). There were significant changes over time regarding reconstruction type, use of primary implants, type of dental restoration, and length of hospital stay. Overall survival after 24 months was 64% (SE 4%) and after 60 months was 42% (SE 4%).

Conclusion

These data reflect a shift in the reconstruction of the maxillary defect afforded by the utilisation of zygomatic implants.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Oncological resection of the maxilla results in a complex defect which can be a challenge to optimally reconstruct and provide dental rehabilitation and function in the context of personalised treatment planning and outcomes. There are several reconstructive options including local tissue flaps, prosthetic obturation, the use of osseointegrated implants, as well as soft tissue and composite free tissue transfer [1, 2]. Many factors influence the most appropriate reconstruction such as the extent of the defect, dental status, motivation of the patient for oral rehabilitation, comorbidity, institutional experience and clinician preferences. The complexity of the defect in part is reflected in the various classifications that have been previously advocated [39] and the options for reconstruction are epitomised by the different algorithms and techniques published over the years [35, 1015]. The reconstruction of the defect might be influenced to a degree, by the relatively poor survival prognosis in those having maxillary resection compared to other head and neck cancer sites, notably oral cavity [16, 17]. This leads to a concept of radical palliative surgery with curative intent, such that for those where cure is ultimately not possible there should ideally be a time of comparatively satisfactory function and quality of life associated with minimal treatment burden and necessity for further hospital procedures. In long-term survivors who are recurrence free, secondary oral rehabilitation adds another level of difficulty with the balance of risk versus benefit especially relevant for those who have had post-operative radiotherapy. In this group the risk of osteoradionecrosis and prosthetic failure versus improvement in appearance, chewing, speech and swallowing must be carefully considered [18]. Many patients do not complete full oral rehabilitation and cope and adapt to their outcome [19].
Given the complexity associated with the maxillary defect, the aim of this study is to report changes in the method of reconstruction and oral rehabilitation of the maxilla since 1994 in our Institution, and to reflect on case mix and survival. For the purpose of this study, there is an emphasis on oral rehabilitation; hence, the maxillary defect has focussed on those resections involving the maxillary alveolus, hard palate, maxillary sinus and nasal complex restricted to Classes 1 to 4 of the Brown classification [7].

Methods

Consecutive head and neck oncology cases involving maxillary resections over a 27-year period between January 1994 and November 2020 at the Liverpool University Foundation NHS Trust were identified from the hospital operating theatre database. The following theatre codes [20] were used to screened eligibility for possible maxillary resection; V06.9 unspecified excision of maxilla, V07.2 partial excision of bone of face, V07.1 extensive excision of bone of face and V07.8 other specified excision of bone of face. Hard palate and maxillary alveolus were considered as part of maxillary resection. Patients were excluded if maxillary surgery had been flagged up in the non-oncology setting, such as osteotomies, temporomandibular surgery, or trauma. Cases with a Brown’s classification of 5 or 6 were also excluded as the focus of the sample were those defects suitable for oral rehabilitation. Datasets from previous research [21, 22] were also searched for cross reference and verified on the electronic hospital records to add cases not identified from the operating theatre database.
Patient data were collected from the electronic case notes, including outpatient clinical letters, multi-disciplinary entries and radiographs. Rehabilitation data were collected from the Liverpool University Dental Hospital Implant Database. Patient clinical and demographic characteristics included the American Society of Anaesthesiologists (ASA) grade [23] site and diagnosis of tumour, operation date, length of stay, Brown’s classification of maxillary resection [7], pathological staging (pTNM) [24], type of flap used for reconstruction, oral rehabilitation, post-operative radio/chemotherapy and survival time.

Ethical approval

The data were collected as part of the clinical audit process and this study was approved by Liverpool University Hospital NHS Foundation Trust Audit Department (CAMS reference 10074).

Statistical analysis

Fisher’s exact test was used to compare categorical data between patient subgroups and the Kruskal–Wallis test was used to compare numerical data. The three time periods analysed were tertiles derived from the number of patients each year over the whole time period. Survival statistics were calculated using the Kaplan–Meier method and the log-rank test. SPSS v25 and STATA v13 were used for the analyses. Given the number of tests, statistical significance was interpreted at the 1% level. A small number of patients were operated on more than once during the study period (6 twice and 1 thrice) and these subsequent operations were excluded from the statistical analysis.

Results

The study sample comprised 186 patients with Brown’s 1–4 maxillary resection seen between 1994 and 2020. Median (IQR) age at primary tumour diagnosis was 69 (59–77) years and 51% (94) were male. Male patients tended to be younger with 23% (22/94) of men aged ≥ 75 years compared to 45% (41/92) of women. Primary tumour site was alveolus for 56% (104), hard palate for 19% (35), maxillary sinus for 18% (34) and nasal for 7% (13). Most (86%, 160) tumours were diagnosed as SCC, 76% (130/172) were pT stage 3–4 and 24% (42/172) were pN positive, with 77% (133/172) being overall stage 3–4. Brown’s classification was level 1 for 26% (48), level 2 for 52% (97), level 3 for 7% (13) and level 4 for 15% (28). ASA was grade 3–4 for 20% (36/179), with 33 grade 3 and 3 grade 4. Surgery alone was used for 40% (75) while for 60% (111) treatment comprised surgery and either radiotherapy, chemotherapy or both. Reconstructive flaps were used for 76% (142), comprising 81 soft flaps and 61 involving hard tissue composite flaps. The main free flaps used were radial (52), anterolateral (27), DCIA (23), scapula (14) and fibula (11). Median (IQR) length of hospital stay (LOS) was 10 (7–16) days.
A fuller breakdown of patient casemix is shown in Table 1, with results also stratified by time period (tertiles), i.e. for 1994–2009, 2010–2015 and 2016–2020. There were significant changes over time in regard to flap reconstruction, LOS, ASA grade and diagnosis. The percentage having flap reconstruction rose from 72% (1994–2009) and 63% (2010–2015) to 91% (2016–2020); the percentages having radial flap reconstructions were 19%, 11% and 51% while the percentages having DCIA flaps were 17%, 17% and 3%. Unsurprisingly the LOS fell over the whole study period, from a median of 15 days (1994–2009) to 10 days (2010–2015) and 9 days (2016–2020). The percentages with ASA grades 3–4 were similar over the 3 time periods, the differences being in the mix of grades 1 and 2 with 18% grade 1’s for 1994–2009, 7% for 2010–2015 and 35% for 2016–2020. All but one of the non-SCC tumours in the study sample were after 2010.
Table 1
Casemix, 1994–2020
 
1994–2009
2010–2015
2016–2020
P value*
Total
 
N
%
N
%
N
%
 
N
%
All patients
54
100
63
100
69
100
 
186
100
Gender
         
 Male
22
41
35
56
37
54
0.24
94
51
 Female
32
59
28
44
32
46
 
92
49
Age (operation)
     
 Median (IQR) years
70 (58–78)
68 (56–78)
71 (63–76)
0.62
69 (59–77)
Site
         
 Alveolus
27
50
32
51
45
65
0.06
104
56
 Hard palate
14
26
16
25
5
7
 
35
19
 Max sinus
11
20
10
16
13
19
 
34
18
 Nasal
2
4
5
8
6
9
 
13
7
Overall P stage
         
 Early (1–2)
7
14
14
25
18
26
0.26
39
23
 Late (3–4)
42
86
41
75
50
74
 
133
77
 NK
5
 
8
 
1
  
14
 
Diagnosis
         
 SCC
53
98
51
81
56
81
0.003
160
86
 Non-SCC***
1
2
12
19
13
19
 
26
14
Browns classification
         
 1
10
19
25
40
13
19
0.04
48
26
 2
32
59
23
37
42
61
 
97
52
 3
2
4
6
10
5
7
 
13
7
 4
10
19
9
14
9
13
 
28
15
 Low level 1–2
42
78
48
76
55
80
0.88
145
78
 High level 3–4
12
22
15
24
14
20
 
41
22
ASA
         
 1
9
18
4
7
24
35
0.002
37
21
 2
30
61
43
70
33
48
 
106
59
 3–4
10
20
14
23
12
17
 
36
20
 NK
5
 
2
 
  
7
 
Treatment
         
 Surgery (S) alone
22
41
30
48
23
33
0.02
75
40
 S and RT primary
1
1
 
1
1
 S and RT post-op
30
56
19
30
36
52
 
85
46
 S and CT
3
5
1
1
 
4
2
 S and RT post-op and CT
2
4
11
17
8
12
 
21
11
 Surgery (S) alone
22
41
30
48
23
33
0.26
75
40
 S and (RT or CT or RTCT)
32
59
33
52
46
67
 
111
60
Flap
         
 No
15
28
23
37
6
9
 < 0.001
44
24
 Soft
13
24
24
38
44
64
 
81
44
 Composite****
26
48
16
25
19
28
 
61
33
Flap detail
         
 None
15
28
23
37
6
9
44
24
 Radial
10
19
7
11
35
51
 
52
28
 ALT
6
11
11
17
10
14
 
27
15
 Lat dorsi
3
6
2
3
3
4
 
8
4
 Rectus abdom
1
2
4
6
 
5
3
 Buccal fat pad
1
2
1
1
 
2
1
 DCIA
9
17
11
17
2
3
 
22
12
 Scapula
5
9
1
2
7
10
 
13
7
 Fibula
4
7
2
3
5
7
 
11
6
 Lat dorsi and DCIA
1
2
 
1
1
 Lat dorsi and scap
1
2
 
1
1
LOS (days)
         
 ≤ 7
8
18
20
36
26
38
 < 0.001
54
32
 8–14
11
24
20
36
32
46
 
63
37
 ≥ 15
26
58
15
27
11
16
 
52
31
 NK
9
 
8
 
  
17
 
 Median (IQR)
15 (9–22)
10 (4–15)
9 (7–13)
0.001
10 (7–16)
RT radiotherapy, CT chemotherapy
*Fishers exact test, apart from use of Kruskal–Wallis test for Age and LOS. NK (not known) groups excluded
**24 of the 130 pN0 were based on clinical grounds only—no neck access with 11 of 41, 3 of 39 and 10 of 50 across the time periods
***Across time periods the 26 non-SCC comprised: acinic cell (0,0,1), adenocarcinoma (0,3,6), ameloblastoma (0,4,0), melanoma (0,2,2), Merkel cell (0,1,0),mucoepidermoid (1,1,0), non-keratinising Schneiderian (0,0,1), Sarcoma (0,0,1), Sinonasal undifferentiated (0,1,0) verrucous (0,0,2)
****For 2 patients, both soft and composite flaps were used (Lat dorsi and scapula, Lat dorsi and DCIA), coded here under composite
No oral rehabilitation was provided for 43% (78/183), while implant supported prostheses were provided for 36% (65/183), non-implant prostheses for 31% (39/183) and both types for 1 patient. There were significant changes over time (Table 2) with implant prostheses provision rising from 22% for 1994–2009 and 29% for 2010–2015 to 52% for 2016–2020; correspondingly, the use of non-implant support declined from 39 to 18% and 12%, respectively. Most implant support was by bridge or retained obturator while most non-Implant support was by obturator. Over time, there was a notable rise after 2015 in the use of a zygomatic implant supported implant bridge and a reduction in other forms of implant support; there was also a steady decline across the study period in the use of non-implant obturator support. Most (91%) implants before 2010 were performed after the primary surgery, while most after 2010 were performed at the same time as initial surgery (67% for 2010–2015 and 92% for 2016–2020). Patients significantly less likely to have rehabilitation (Table 3) were those with high-level Browns classification (63% level 3–4 vs 37% level 1–2), those treated by surgery with radiotherapy and chemotherapy (76%) compared with 33% for surgery alone and 40% for surgery with either radiotherapy or chemotherapy but not both, those with flap reconstruction (60% composite, 43% soft, 18% no flap), younger patients (57% if < 65 years, 40% if 65–74 years and 29% if ≥ 75 years), and those with longer LOS (28% if ≤ 7 days, 43% if 8–14 days and 57% if ≥ 15 days). For those that had rehabilitation, there were no notable associations amongst the casemix variables with whether the rehabilitation was implant or non-implant supported (Table 3).
Table 2
Rehabilitation, 1994–2020
 
1994–2009
2010–2015
2016–2020
P value*
Total
 
N
%
N
%
N
%
 
N
%
All patients
54
100
63
100
69
100
 
186
100
Rehabilitation (prostheses)
         
 None provided
20
39
33
52
25
36
 < 0.001
78
43
 Implant
11
22
18
29
36
52
 
65
36
 Non-implant
20
39
11
17
8
12
 
39
21
 Both types
 
1
2
  
1
1
 NK
3
 
 
  
3
 
Rehabilitation detail
         
 None provided
20
39
33
52
25
36
 
78
43
 Implant:
         
 Bridge
1
 
5
 
30
  
36
 
 Retained obturator
6
 
9
 
1
  
16
 
 Retained overdenture
2
 
3
 
1
  
6
 
 Crown
 
 
1
  
1
 
 Nasal/facial
 
1
 
2
  
3
 
 Orbital and overdenture
1
 
 
  
1
 
 Bridge and orbital
1
 
 
1
  
2
 
 Non-implant:
         
 Obturator
16
 
9
 
3
  
28
 
 Denture
 
1
 
3
  
4
 
 Orbital
4
 
1
 
1
  
6
 
 Direct and indirect restoration
 
 
1
  
1
 
 Other:
         
 Implant bridge and non-implant obturator
 
1
 
  
1
 
Months from operation to implant
         
 Known for
11
 
18
 
36
  
65
 
 Median (IQR)
22 (10–31)
0 (0–4)
0 (0–0)
 < 0.001
0 (0–2)
 Same day as operation
1
9
12
67
33
92
 < 0.001
46
71
*Fishers exact test, apart from use of Kruskal–Wallis test for months between operation and implant
Table 3
Casemix and rehabilitation
 
Total
No rehab
Implant rehab**
Non-implant rehab
P value*
(no rehab vs yes)
P value*
Implant vs non-implant (if rehab)
  
N
%
N
%
N
%
All patients
183
78
43
66
36
39
21
Gender
         
 Male
91
48
53
28
31
15
16
0.007
0.84
 Female
92
30
33
38
41
24
26
  
Age (operation)
         
 < 65
68
39
57
19
28
10
15
0.004
0.19
 65–74
52
21
40
23
44
8
15
  
 ≥ 75
63
18
29
24
38
21
33
  
Site
         
 Alveolus
102
40
39
38
37
24
24
0.12
0.12
 Hard palate
35
12
34
17
49
6
17
  
 Max sinus
33
20
61
5
15
8
24
  
 Nasal
13
6
46
6
46
1
8
  
Overall P stage
         
 Early (1–2)
39
12
31
16
41
11
28
0.07
0.64
 Late (3–4)
130
62
48
45
35
23
18
  
NK
14
4
 
5
 
5
   
Diagnosis
         
 SCC
157
68
43
57
36
32
20
0.68
0.58
 Not SCC
26
10
38
9
35
7
27
  
Browns classification
         
 1
47
17
36
16
34
14
30
0.02
0.02
 2
96
36
38
43
45
17
18
  
 3
13
10
77
2
15
1
8
  
 4
27
15
56
5
19
7
26
  
 Low level 1–2
143
53
37
59
41
31
22
0.006
0.10
 High level 3–4
40
25
63
7
18
8
20
  
ASA
         
 1
35
20
57
12
34
3
9
0.13
0.36
 2
106
40
38
39
37
27
25
  
 3–4
35
14
40
13
37
8
23
  
 NK
7
4
 
2
 
1
   
Treatment
         
 Surgery (S) alone
75
25
33
28
37
22
29
 < 0.001
0.14
 S and RT primary
1
1
100
 
   
 S and RT post-op
82
32
39
33
40
17
21
  
 S and CT
4
4
100
 
   
 S and RT post-op and CT
21
16
76
5
24
   
 Surgery (S) alone
75
25
33
28
37
22
29
0.05
0.23
 S and (RT or CT or RTCT)
108
53
49
38
35
17
16
  
Flap
         
 None
44
8
18
17
39
19
43
 < 0.001
0.05
 Soft
81
35
43
34
42
12
15
  
 Composite
58
35
60
15
26
8
14
  
LOS (days)
         
 ≤ 7
54
15
28
23
43
16
30
0.01
0.02
 8–14
63
27
43
29
46
7
11
  
 ≥ 15
49
28
57
10
20
11
22
  
 NK
17
8
 
4
 
5
   
RT radiotherapy, CT chemotherapy
*Fishers exact test, excluding NK (not known) where applicable
**One case supported by both implant and non-implant prostheses was grouped under implant
***22 of the 127 pN0 were based on clinical grounds only—no neck access with 5 of 78, 9 of 66 and 8 of 39 across the three groups
The use of reconstructive flaps (76% overall) was associated significantly with many of the casemix variables (Table 4). Flap use was higher for patients with maxillary sinus tumours, more advanced tumour staging, high-level Browns classification, treated with radiotherapy and/or chemotherapy in addition to the surgery, and for patients with longer LOS. For those that had flap reconstructions, the most notable indicators towards having composite rather than soft flaps were younger age (62% 34/55 for < 65 years, 31% 27/87 for ≥ 65 years), more advanced tumour staging (50% 58/117 for late 3–4 overall stage, 5% (1/21) for earlier staging), involvement of radiotherapy and/or chemotherapy treatment (52% 53/101 with, 20% 8/41 without) and longer LOS (47% 51/108 ≥ 8 days, 17% 4/23 ≤ 7 days). For those without a flap, the median (IQR) LOS was 3 (1–7) days, compared to 11 (7–18) days with soft flap and 14 (10–17) days with composite flap, Kruskal–Wallis test P < 0.001 comparing all 3 groups and P = 0.02 (borderline sign) comparing soft flap with composite flap.
Table 4
Casemix and type of flap
 
Total
No flap
Soft flap
Composite flap
P value*
(no flap vs yes)
P value*
Soft vs composite)
(if flap)
 
N
%
N
%
N
%
All patients
186
44
24
81
44
61
33
Gender
         
 Male
94
15
16
38
40
41
44
0.02
0.02
 Female
92
29
32
43
47
20
22
  
Age (operation)
         
 < 65
68
13
19
21
31
34
50
0.10
0.001
 65–74
55
10
18
30
55
15
27
  
 ≥ 75
63
21
33
30
48
12
19
  
Site
         
 Alveolus
104
29
28
46
44
29
28
 < 0.001
0.28
 Hard palate
35
12
34
14
40
9
26
  
 Max sinus
34
18
53
16
47
  
 Nasal
13
3
23
3
23
7
54
  
Overall P stage
         
 Early (1–2)
39
18
46
20
51
1
3
 < 0.001
 < 0.001
 Late (3–4)
133
16
12
59
44
58
44
  
 NK
14
10
 
2
 
2
   
Diagnosis
         
 SCC
160
34
21
71
44
55
34
0.08
0.79
 Not SCC
26
10
38
10
38
6
23
  
Browns classification
         
 1
48
25
52
17
35
6
13
 < 0.001
0.05
 2
97
19
20
47
48
31
32
  
 3
13
4
31
9
69
  
 4
28
13
46
15
54
  
 Low level 1–2
145
44
30
64
44
37
26
 < 0.001
0.02
 High level 3–4
41
17
41
24
59
  
ASA
         
 1
37
3
8
20
54
14
38
0.03
0.89
 2
106
29
27
43
41
34
32
  
 3–4
36
10
28
16
44
10
28
  
 NK
7
2
 
2
 
3
   
Treatment
         
 Surgery (S) alone
75
34
45
33
44
8
11
 < 0.001
0.002
 S and RT primary
1
1
100
  
 S and RT post-op
85
9
11
37
44
39
46
  
 S and CT
4
2
50
2
50
  
 S and RT post-op and CT
21
1
5
9
43
11
52
  
 Surgery (S) alone
75
34
45
33
44
8
11
 < 0.001
 < 0.001
 S and (RT or CT or RTCT)
111
10
9
48
43
53
48
  
LOS (days)
         
 ≤ 7
54
31
57
19
35
4
7
 < 0.001
0.02
 8–14
63
5
8
33
52
25
40
  
 ≥ 15
52
2
4
24
46
26
50
  
 NK
17
6
 
5
 
6
   
RT radiotherapy, CT chemotherapy
*Fishers exact test, excluding NK (not known) where applicable
**24 of the 130 pN0 were based on clinical grounds only—no neck access with 12 of 44, 7 of 81 and 5 of 61 across the three groups
Overall survival after 24 months was 64% (SE 4%) and after 60 months was 42% (SE 4%). Casemix factors most strongly associated with better survival (Table 5) were less advanced tumour staging, rehabilitation support and a shorter LOS. Survival curves by pTN staging and by Browns classification are shown in Figs. 1 and 2 respectively. The overall recurrence rate was 40% (74/186), with little difference noted when analysed by Browns classification (Level 1: 40%, 19/48, Level 2: 40%, 39/97, Level 3: 38%, 5/13, Level 4: 39%, 11/28).
Table 5
Kaplan–Meier survival by casemix and rehabilitation
 
Known for
12 months
24 months
36 months
48 month
60 months
P value*
All patients
183
79 (3)
64 (4)
56 (4)
46 (4)
42 (4)
 
Time period
       
 1994–2009
54
81 (5)
64 (7)
57 (7)
47 (7)
41 (7)
0.71
 2010–2015
60
70 (6)
63 (6)
58 (7)
46 (7)
43 (7)
 
 2016–2020
69
85 (5)
61 (7)
52 (8)
44 (9)
NA
 
Gender
       
 Male
93
76 (5)
64 (5)
58 (5)
46 (6)
40 (6)
0.88
 Female
90
81 (4)
63 (5)
55 (6)
47 (6)
43 (6)
 
Age
       
 < 65
67
77 (5)
65 (6)
62 (6)
53 (7)
53 (7)
0.04
 65–74
54
81 (5)
68 (7)
60 (7)
51 (8)
36 (8)
 
 ≥ 75
62
78 (5)
58 (7)
48 (7)
35 (7)
32 (7)
 
Site
       
 Alveolus
101
81 (4)
63 (5)
53 (5)
48 (6)
45 (6)
0.31
 Hard palate
35
83 (6)
71 (8)
68 (8)
55 (9)
47 (9)
 
 Max sinus
34
76 (7)
63 (9)
59 (9)
39 (10)
32 (10)
 
 Nasal
13
49 (17)
49 (17)
49 (17)
33 (18)
17 (15)
 
Overall P stage
       
 Early (1–2)
38
97 (3)
81 (7)
71 (8)
59 (9)
59 (9)
0.007
 Later (3–4)
132
73 (4)
56 (5)
51 (5)
41 (5)
36 (5)
 
Diagnosis
       
 SCC
158
79 (3)
62 (4)
54 (4)
44 (4)
40 (4)
0.63
 No SCC
25
75 (9)
70 (10)
65 (10)
58 (11)
52 (12)
 
Browns classification
       
 Low (1–2)
142
78 (4)
62 (4)
53 (5)
46 (5)
41 (5)
0.67
 High (3–4)
41
83 (6)
70 (7)
64 (8)
47 (8)
44 (8)
 
ASA
       
 1
37
87 (6)
56 (9)
52 (9)
36 (9)
36 (9)
0.97
 2
103
76 (4)
67 (5)
57 (5)
49 (5)
43 (6)
 
 3–4
36
78 (7)
62 (9)
58 (9)
44 (10)
39 (10)
 
Treatment
       
 Surgery (S) alone
73
84 (4)
73 (5)
67 (6)
59 (6)
53 (7)
0.02
 S and (RT or CT or RTCT)
110
75 (4)
57 (5)
49 (5)
37 (5)
34 (5)
 
Flap
       
 No
42
85 (6)
80 (6)
69 (7)
57 (8)
51 (8)
0.18**
 Soft
81
77 (5)
60 (6)
55 (6)
43 (6)
41 (6)
 
 Composite
60
77 (6)
56 (7)
49 (7)
42 (7)
37 (7)
 
LOS (days)
       
 ≤ 7
53
89 (4)
79 (6)
70 (7)
57 (8)
53 (9)
0.004
 8–14
63
71 (6)
64 (6)
53 (7)
41 (7)
38 (7)
 
 ≥ 15
52
77 (6)
47 (7)
44 (7)
35 (7)
32 (7)
 
Rehabilitation (Prostheses)
       
 None provided
75
70 (5)
47 (6)
41 (6)
26 (6)
26 (6)
0.001
 Non-implant
39
87 (5)
71 (7)
62 (8)
52 (9)
45 (9)
 
 Implant
65
83 (5)
80 (5)
72 (6)
70 (7)
62 (8)
 
RT radiotherapy, CT chemotherapy, NA not applicable
*Log-rank test, excluding NK (not known) where applicable
**P = 0.07 for flap (soft or composite) vs no flap

Discussion

Controversy remains regarding the most appropriate reconstruction and oral rehabilitation for the post-oncology maxillary defect. As treatments become more refined over time, there is merit in reflecting back over several decades as this allows an opportunity to report changes in treatment strategies, survival and rehabilitation outcomes. Although the data are limited to one Institution, it represents a substantial series collated over many years. It is accepted that as a retrospective casenote review, there are various other aspects that are important which it has not been possible to report in this study, such as post-operative complications, donor site morbidity and health-related quality of life (HRQOL).
In our sample, Brown’s classification 1 and 2 predominate (78% of cases). In this relatively low-level defect, the main component of dysfunction in form and function is related to the teeth and the surgically created fistula between the oral cavity and the nose/maxillary sinus. The importance of oral function to HRQOL is well recognised [25] and issues of chewing, dental appearance, teeth, speech are amongst the commonest concerns [26]. Oral rehabilitation has a critical role in promoting optimal patient reported outcomes [25, 27]. The pathology, whether benign or malignant is an important consideration in terms of resection and reconstruction. In this case series, the focus has been on cancer and unsurprisingly the majority were squamous cell carcinoma. Over the time period of this study, there has been centralisation of the service [28] and this might account for variations in pathology where some earlier cases would have been managed in the surrounding hospitals and not referred. Resection for benign disease such as pleomorphic adenoma tends to be less destructive in relation to achieving margins and post-operative radiotherapy can be avoided. In our oncology cohort, over half of patients received post-operative radiotherapy and this is an important consideration in respect to treatment burden, and the scope for successful primary or secondary oral rehabilitation. Another essential aspect is the tumour stage and hence prognosis. Three quarters were pathological stage 3 or 4 and a quarter had cervical lymph node metastases. With advanced stage disease, the rates of failure over the first 2 years increase and there is a management imperative to help enable the patient to achieve the best possible HRQOL in the time remaining. In addition, specifically in this group, the burden of additional treatments should be minimised, for example, the need for multiple hospital visits for oral rehabilitation, further surgery, and modifications to the prosthesis. Ideally, there needs to be coordinated multi-disciplinary clinical review.
The series presented demonstrates that there is a definite place for obturation. Of the 45 patients, around one-third were implant retained and the remainder were managed without implants. In terms of the preferred methods of reconstruction, there has been a notable change over time. The vast majority of patients now have microvascular free tissue transfer. Furthermore, there has been less reliance on composite flaps to restore the defect with around half in last 5 years having radial free flaps. This has been accompanied by a reduction in hospital length of stay. The main driver for this change is the more frequent use of remotely anchored zygomatic implants to support the prosthesis [2933]. With this technique, there is less reliance on bone transfer and an increasing focus on primary placement of zygomatic implants at the time of surgery. In terms of soft tissue, both the radial and the anterolateral thigh (ALT) free flaps have long pedicle lengths and this facilitates the ease of anastomosis in the neck. However, the ALT can be a bit too bulky for zygomatic implant perforation and subsequent fitting of the suprastructure. Despite the significant challenges, the ZIP flap technique provides full dental rehabilitation within 30 days of surgery and prior to radiotherapy if this is required, with excellent published patient reported outcomes [33]. There is a need for a bony free flap in the higher level maxillectomy defects [3], however, the Brown 3 and 4 defects are less common. Another factor which has influenced the change in practice is the recognition that in those patients in the past with relatively low-level defects and bony flap, the bone tended not to be used for oral rehabilitation and was not critical for restoration of facial profile. In addition, there has been concern regarding the placement of secondary implants in the irradiated field. Although optimal rehabilitation might not be achieved without the use of implant retention, their placement carries the risk of implant failure and osteoradionecrosis, and might confer only modest improvements in function and HRQOL [25, 32]. Another factor that limits delayed oral rehabilitation is that a proportion develops loco-regional failure and are not surviving after 2 years [17, 3436]. It is encouraging that 64% in this cohort were alive after 24 months and 42% after 60 months. Tumour pathology is the main factor associated with survival factor but perhaps in a larger future sample it might be possible to tease out the relative risk of avoiding post-operative radiotherapy (de-escalation) in the low-level maxillectomy and report the benefit of this in terms of trade-off in treatment burden, side-effects and HRQOL.
There is still a place for composite free tissue alone, especially in the extensive resections, to provide adequate function and HROQOL, accepting that formal oral rehabilitation will not be achieved [19]. However, the emergence of zygomatic implants informs the previous algorithms for maxillary reconstruction [35, 1015]. It is accepted that the utilisation of this approach relies on the experience and expertise of the clinician placing the implants and the maxillofacial prosthodontic team providing the prosthesis. This resource is available in our Institution and has allowed this approach to be routinely considered. Some units might wish to use computer-derived models and guides to assist with the placement of bone and implants at the time of primary surgery [3739]. Whatever techniques are used to facilitate the accurate placement of the implants the imperative remains for these to be used for rehabilitation without undue delay.
In conclusion, there has been a change in the pattern on reconstruction of the maxillary defect over the last 3 decades. The majority now have free tissue reconstruction and there is a stronger emphasis on the incorporation of primary zygomatic implants and oral rehabilitation via early-loaded implant supported fixed bridge reconstruction. Although the prognosis is still relatively poor, early meaningful rehabilitation is feasible and the combination of zygomatic implants has changed the paradigm as to the optimal microvascular reconstruction.

Acknowledgements

Other consultants if not co-authors

Declarations

The study complied with all aspects of ethical standards of clinical research.

Conflict of interest

We do not have financial disclosure or any conflict of interest.

Ethical approval

The data were collected as part of the clinical audit process and this study was approved by Liverpool University Hospital NHS Foundation Trust Audit Department (CAMS reference 10074).
The data were collected as part of routine clinical care, anonymised, collated, and analysed, and thus no individual patient consent was sought.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med HNO

Kombi-Abonnement

Mit e.Med HNO erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes HNO, den Premium-Inhalten der HNO-Fachzeitschriften, inklusive einer gedruckten HNO-Zeitschrift Ihrer Wahl.

Literatur
9.
Zurück zum Zitat Akinmoladun VI, Dosumu OO, Olusanya AA, Ikusika OF (2013) Maxillectomy defects: a suggested classification scheme. Afr J Med Med Sci 42(2):171–175PubMed Akinmoladun VI, Dosumu OO, Olusanya AA, Ikusika OF (2013) Maxillectomy defects: a suggested classification scheme. Afr J Med Med Sci 42(2):171–175PubMed
10.
Zurück zum Zitat Boyes-Varley JG, Howes DG, Davidge-Pitts KD, Brånemark I, McAlpine JA (2007) A protocol for maxillary reconstruction following oncology resection using zygomatic implants. Int J Prosthodont 20(5):521–531PubMed Boyes-Varley JG, Howes DG, Davidge-Pitts KD, Brånemark I, McAlpine JA (2007) A protocol for maxillary reconstruction following oncology resection using zygomatic implants. Int J Prosthodont 20(5):521–531PubMed
19.
Zurück zum Zitat Petrides GA, Hicks G, Dunn M, Froggatt C, Wallace C, Howes D, Leinkram D, Low TH, Ch’ng S, Wykes J, Palme CE, Clark JR (2021) Dentoalveolar outcomes in maxillary reconstruction: a retrospective review of 85 maxillectomy reconstructions. ANZ J Surg 91(7–8):1472–1479. https://doi.org/10.1111/ans.17001 (Epub 2021 Jun 14)CrossRefPubMed Petrides GA, Hicks G, Dunn M, Froggatt C, Wallace C, Howes D, Leinkram D, Low TH, Ch’ng S, Wykes J, Palme CE, Clark JR (2021) Dentoalveolar outcomes in maxillary reconstruction: a retrospective review of 85 maxillectomy reconstructions. ANZ J Surg 91(7–8):1472–1479. https://​doi.​org/​10.​1111/​ans.​17001 (Epub 2021 Jun 14)CrossRefPubMed
24.
Zurück zum Zitat Lydiatt WM, Patel SG, Osullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122–137. https://doi.org/10.3322/caac.21389 (Epub 2017 Jan 27)CrossRefPubMed Lydiatt WM, Patel SG, Osullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122–137. https://​doi.​org/​10.​3322/​caac.​21389 (Epub 2017 Jan 27)CrossRefPubMed
26.
Zurück zum Zitat Kanatas A, Ghazali N, Lowe D, Udberg M, Heseltine J, O’Mahony E, Rogers SN (2013) Issues patients would like to discuss at their review consultation: variation by early and late stage oral, oropharyngeal and laryngeal subsites. Eur Arch Otorhinolaryngol 270(3):1067–1074. https://doi.org/10.1007/s00405-012-2092-6 (Epub 2012 Jun 29)CrossRefPubMed Kanatas A, Ghazali N, Lowe D, Udberg M, Heseltine J, O’Mahony E, Rogers SN (2013) Issues patients would like to discuss at their review consultation: variation by early and late stage oral, oropharyngeal and laryngeal subsites. Eur Arch Otorhinolaryngol 270(3):1067–1074. https://​doi.​org/​10.​1007/​s00405-012-2092-6 (Epub 2012 Jun 29)CrossRefPubMed
27.
Zurück zum Zitat Pace-Balzan A, Butterworth C, Lowe D, Rogers SN (2009) The responsiveness of the Liverpool oral rehabilitation questionnaire (LORQ): a pilot study. Int J Prosthodont 22(5):456–458PubMed Pace-Balzan A, Butterworth C, Lowe D, Rogers SN (2009) The responsiveness of the Liverpool oral rehabilitation questionnaire (LORQ): a pilot study. Int J Prosthodont 22(5):456–458PubMed
28.
33.
38.
Zurück zum Zitat Seikaly H, Idris S, Chuka R, Jeffery C, Dzioba A, Makki F, Logan H, O’Connell DA, Harris J, Ansari K, Biron V, Cote D, Osswald M, Nayar S, Wolfaardt J (2019) The alberta reconstructive technique: an occlusion-driven and digitally based jaw reconstruction. Laryngoscope 129(Suppl 4):S1–S14. https://doi.org/10.1002/lary.28064 (Epub 2019 Jun 26)CrossRefPubMed Seikaly H, Idris S, Chuka R, Jeffery C, Dzioba A, Makki F, Logan H, O’Connell DA, Harris J, Ansari K, Biron V, Cote D, Osswald M, Nayar S, Wolfaardt J (2019) The alberta reconstructive technique: an occlusion-driven and digitally based jaw reconstruction. Laryngoscope 129(Suppl 4):S1–S14. https://​doi.​org/​10.​1002/​lary.​28064 (Epub 2019 Jun 26)CrossRefPubMed
Metadaten
Titel
Changing trends in the microvascular reconstruction and oral rehabilitation following maxillary cancer
verfasst von
Simon N. Rogers
Ashni Adatia
Stephanie Hackett
Angela Boscarino
Anika Patel
Derek Lowe
Christopher J. Butterworth
Publikationsdatum
01.02.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 8/2022
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-022-07277-y

Weitere Artikel der Ausgabe 8/2022

European Archives of Oto-Rhino-Laryngology 8/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.